On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now Blog

Stocks on Radar

NeutriSci International Inc. (TSX.V: NU) (OTCQB: NRXCF) (FRA: 1N9) – From Nutraceuticals to Cannabinoid Pharmaceuticals

  • Patented nutraceuticals with retail distribution and consumer branding expertise
  • MOU with cannabinoid pharma for research on NeutriSci products for new therapeutics
  • Targeting forefront of new and innovative cannabinoid-based medical products in Canada

In business for nearly a decade, NeutriSci International Inc. (TSX.V: NU) (OTCQB: NRXCF) (FRA: 1N9) has become an established leader in the Canadian nutraceutical markets and continues to develop new sales channels throughout the U.S., Europe and Asia. The company is not only expanding its existing national retail footprint in Canada; it just entered into a major R&D Memorandum of Understanding with Scientus Pharma Inc. to develop, produce and distribute medical cannabinoid products for existing retail distribution networks across Canada.

With a history of specializing in the original formulation and production of products full of health-giving additives and clinically proven medicinal benefit, NeutriSci is recognized for product safety, quality and efficacy. Its sugar free Neuenergy® is a clinically proven, great tasting chewable tablet that provides a quick boost of energy and sharpens focus. Each tablet contains the equivalent anti-oxidants of 25,000 fresh blueberries. These anti-oxidants have a high level of bioavailability, and research suggests that “pterostilbene” is even more powerful than resveratrol.

“Neuenergy represents a healthy alternative to traditional energy products,” Canadian and International tennis star Genie Bouchard stated in a news release. Recognized throughout Canada and in tennis circles around the world, Bouchard recently inked a sponsorship deal with NeutriSci and said she’s “excited to partner with one of Canada’s up and coming brands.”

NeutriSci also produces its BlūScience™ line of products targeting memory, heart, anti-aging, weight management and focus & energy, all of which combine pterostilbene (pTeroPure) with other proprietary and specific health enhancing ingredients. One BlūScience™ capsule provides the same amount of pterostilbene found in over 500 cartons of blueberries. BlūScience products are specifically designed to support optimal health.

NeutriSci also plans to begin selling nu.thc™ and nu.cbd™ in Canada soon. These healthy, sugar-free cannabinoid tablets represent a market first and offer a metered dose of THC/CBD, combined with the increased bioavailability and powerful antioxidant properties of 125mg of the company’s patented pterostilbene.

The next big development for NeutriSci will likely come from its recently signed R&D Memorandum of Understanding with Scientus Pharma, a vertically-integrated biopharmaceutical focused on developing and commercializing pharmaceutical-grade medicinal cannabinoid derivative products.

NeutriSci’s products and their components are a natural fit for Scientus Pharma, which aims to develop new cannabinoid-based medicines. NeutriSci’s products have clinically proven anti-oxidant properties, enhance bioavailability and provide other health benefits, and Scientus Pharma will conduct research on NeutriSci’s products and their components in combination with various cannabinoids to develop new therapeutics. NeutriSci will initially bankroll the research activities, and both companies will have rights for further product development, testing and potential clinical trials.

“NeutriSci brings a wealth of retail distribution and consumer branding expertise,” Scientus Chairman Har Grover stated in a news release. “They have had success innovating with Neuenergy® and the brand has good presence in several health and wellness settings. Pterostilbene and related compounds present interesting targets for further research and we are looking forward to this collaboration.”

NeutriSci President Glen Rehman stated, “This Scientus Pharma partnership helps position us at the forefront of developing new and innovative cannabinoid based medical products in Canada. Scientus Pharma, along with its existing partnerships, is sure to be a dominant player in the cannabis space in Canada. Through a collaborative effort, we will incorporate NeutriSci’s IP, technology and ingredients with Scientus’ expertise, proprietary technical know-how, and resources. By leveraging both parties existing partnerships, we will be positioned to offer the national retail consumer a safe, effective, dose controlled product that completes our ‘plant to blood stream’ strategy.”

The R&D Memorandum of Understanding with Scientus Pharma will combine NeutriSci’s patented healthy products, retail distribution and consumer branding expertise with a leading cannabinoid biopharmaceutical intent on creating new therapeutics. As NeutriSci President Glen Rehman stated, it will “…position us at the forefront of developing new and innovative cannabinoid based medical products in Canada.”

This partnership could make an indelible mark in Canadian cannabis.

For more information, visit the company’s website at www.NeutriSci.com

For JGR Capital’s Research Note on NeutriSci International, see http://ibn.fm/Iiqwx

India Globalization Capital, Inc. (NYSE: IGC) Anticipates Filing Patents for Portfolio of Drug Candidates in 2018-2019

  • Included are drugs formulated to treat Alzheimer’s, Parkinson’s, eating disorders and seizures
  • IGC already has seven provisional filings for phytocannabinoid-based combination therapies
  • Company also has in its pipeline combination therapy drug candidates for the treatment of end points of Parkinson’s, as well as epilepsy in cats and dogs

India Globalization Capital, Inc. (NYSE American: IGC) anticipates filing, in 2018 and 2019, for international Patent Cooperation Treaty (“PCT”) patents, as well as U.S. national patent filings, for a portfolio of drugs (http://ibn.fm/Ncgz0).

Its drug for the treatment of Alzheimer’s (IGC-AD1) is anticipated for patent filings in PCT and the U.S. in 2018. Its seizure drug (IGC-505) is scheduled for filing for a U.S. patent in late 2018. The company’s eating disorders drug (IGC-504) is anticipated for filing for a U.S. patent late this year, while another eating disorders drug (IGC-506) is anticipated for filing for a PCT patent in 2018 and a U.S. filing in 2019. This portfolio encompasses the company’s drugs that are formulated to treat seizures, Alzheimer’s and eating disorders — representing large domestic and international markets.

For its drug formulated to treat Alzheimer’s, as described in a SeeThruEquity update on IGC (http://ibn.fm/5fBi8), it has formulated a cannabis-based combination which treats endpoints of the disease such as plaques, tangles, anxiety and agitation. IGC plans to market its patent-pending drug through U.S. and Canadian medical dispensaries in early 2018. A key goal for the company in 2018 is to get its lead product formulation, Hyalolex, ready for phase IIB human trials. IGC estimates that Alzheimer’s disease costs the U.S. economy alone roughly $236 billion annually. It affects more than 5.3 million Americans, and more than 65 percent of its patients are women.

IGC is a Maryland-based company with two lines of businesses. One is legacy, which includes the rental of heavy equipment, real estate management and commodities trading. The second is canna-pharmaceutical. That business is focused on developing a formulation using cannabis extracts for the treatment of many diseases.

For more information, visit the company’s website at www.IGCInc.us

Choom™ (CSE: CHOO) (OTCQB: CHOOF) Cultivating an Exceptional Consumer Experience

  • Branding and retail focused to capture large share of $8.7 billion Canadian recreational cannabis market
  • Developing chain of branded retail cannabis dispensaries – just announced new retail store concept
  • Intends to establish a significant retail footprint in the Canadian recreational cannabis markets

The laid back Hawaiian lifestyle is the envy of the world. Surfers and sun worshipers enjoy life and, for decades, have relaxed with ‘choom’, the local name for marijuana. Now a company, Choom™ (CSE: CHOO) (OTCQB: CHOOF) is bringing the spirit and lifestyle of Hawaii to Canada. Choom™ is a high-quality hand-crafted cannabis brand created exclusively for the Canadian recreational market. Headquartered in Vancouver, British Columbia, Choom™ intends to become a recognized market leader in reaching the Canadian cannabis consumer by developing a chain of branded retail cannabis dispensaries in strategic Canadian jurisdictions.

Choom retail stores will provide discriminating cannabis consumers a unique, modern environment, as well as a welcoming atmosphere for curious neophytes. Cultivating an exceptional consumer experience is an essential segment of Choom’s overarching retail distribution strategy. A strong retail identity and powerful branding will set Choom apart in a newly launched national recreational cannabis market.

To bring the Choom vibe to life and create exactly the right image, environment and experience, the company just announced its new retail store concept design and engaged a design team responsible for some of the most recognized retail environments in Canada (http://ibn.fm/Gx98n). In a news release, Juli Hodgson, president of Hodgson Design Associates, stated, “We wanted to create a retail experience for Choom™ that measured up to stores in any industry. We wanted to be able to translate the brand into a welcoming physical and operational environment. Immersive store design will be critical to retail success in an industry destined for explosive growth”.

The company is led by a successful, seasoned professional. Chris Bogart, president and CEO of Choom™, has over two decades of international experience in capital markets. Bogart has been directly involved in multiple operating companies, active in M&A and equity financings, and has raised in excess of $100M for public and private companies. Bogart was a co-founder of InMed Pharmaceuticals (CSE: IN) and a co-founder of Magnum Uranium, which was acquired by TSX-listed Energy Fuels.

Excited about Choom’s latest developments, Bogart commented, “As the Canadian market approaches a new cannabis recreation marketplace, meeting consumer perception and choice with social credibility will be key.”

The legalization of recreational cannabis is slated for July 2018 in Canada, and licensed producers are vying for retail recognition in preparation for the expected tsunami of recreational demand. For the majority of cannabis companies, retail distribution is almost an afterthought, but branding and retail positioning will be paramount in capturing an out-sized share of the estimated $8.7 billion annual recreational marijuana in Canada. By cultivating an exceptional consumer experience, Choom™ intends to establish a significant retail footprint and also become a recognized leader in the Canadian recreational cannabis markets.

For more information, visit the company’s website at www.Choom.ca

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Technology Offers Potentially Safer Method of Delivering Drug Therapies

  • Only company in the world with patent for the oral or ingestible delivery of all non-psychoactive cannabinoids
  • Uplisted to OTCQX® Best Market
  • Licensing model generates profit margins in excess of 90 percent

A new report by the National Academies of Sciences, Engineering and Medicine is the most comprehensive analysis of existing research on e-cigarettes, according to the New York Times (http://ibn.fm/v4WGq). While warning against the risk of nicotine addiction posed by vaping, the report claimed “that the devices are safer than traditional smoking products and may help smokers quit, citing conclusive proof that switching can reduce smokers’ exposure to deadly tar, dangerous chemicals and other carcinogens.” Although nicotine is most often cited in indictments against smoking, it is not a carcinogen and appears to have little effect on cardiovascular health. Indeed, its use has been credited with health benefits (http://ibn.fm/jAT9G), with its bad rap being attributed to its method of delivery, such as inhaling tobacco smoke. This report highlights the importance of drug delivery methodologies like those developed by Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP). The company, recently uplisted to the OTCQX® Best Market, has developed technology that allows nicotine to be absorbed without smoking.

Lexaria’s DehydraTECH™ oral digestion technology is a ‘back office’ process that allows non-psychoactive cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and nicotine to be absorbed at much higher rates. The company has been working with the National Research Council of Canada (“NRC”), an agency of the Canadian federal government, to explore the effects of its technology. Lexaria’s superior delivery system offers the promise of potentially reducing required doses of these substances, since less of them goes to waste. The technology also speeds up delivery. It can deliver payload molecules to the bloodstream in 15-25 minutes, as opposed to the 60-90 minutes required for current methods, and is already in use in a number of consumer products. The technology is already attracting the attention of Big Pharma, and Lexaria is in negotiations with major pharmaceutical companies to license its technology. The smallest deal with any one of these could increase revenues by over $1 million, and the largest could increase revenues by much, much more, as noted by CEO Chris Bunka in a recent interview (http://ibn.fm/uiQhc). Lexaria’s licensing model will generate revenues at very little cost, leaving upward of 90 percent of revenues as profit.

Presently, Lexaria is the only company in the world that has been awarded a patent for the improved (oral or ingestible, including pills) delivery of all non-psychoactive cannabinoids. Patents have been awarded in the U.S. and Australia and are pending in 40 more countries. This puts the company in the unusually advantageous position of owning proprietary technology that can deliver a vast range of non-psychoactive cannabinoid-based drugs. Rather than being a competitor to clinical stage biotech companies, Lexaria plans to be an enabler.

Earlier this month, OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, announced that Lexaria Bioscience Corp. had qualified to trade on the OTCQX® Best Market (http://ibn.fm/PEtLq). Lexaria upgraded to OTCQX from the OTCQB® Venture Market. To qualify for the OTCQX market, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws and have a professional third-party sponsor introduction. Penny stocks, shells and companies in bankruptcy cannot qualify for OTCQX. Per the OTC Markets website, the companies found on OTCQX are distinguished by the integrity of their operations and diligence with which they convey their qualifications.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

Caveat Emptor: Blockchain and Crypto Companies under SEC Scrutiny

The mania surrounding bitcoin and other cryptocurrencies has now overflowed onto the underlying technology. The real value of cryptocurrencies is hotly in dispute, but there is consensus that the underlying blockchain technology has applications that extend far beyond its connections to cryptocurrency. IBM’s Martin Schroeter recently told CNBC (http://ibn.fm/Ln0L9), “Blockchain, the digital record-keeping method that exploded in popularity in conjunction with the cryptocurrency craze, will change the way the world makes transactions.” Unfortunately, the unscrupulous will always make every conceivable attempt to capitalize on a current craze and redouble efforts during transformative events.

Spring-boarding off the cryptocurrency craze, little-known companies have been announcing plans to enter the bitcoin industry or into its underlying distributed ledger blockchain technology. An encrypted electronic ledger, blockchain has the potential to dramatically reduce business costs, efficiently streamline operations and provide data security and reliability. Replicated across a network of multiple computer nodes, the records keeping system is decentralized, self-monitored by all the linked computers and eliminates the need for supervision and administration of records. Little wonder that IBM as well as multiple other well-known global companies have begun blockchain initiatives.

However, public companies that change their names or business models with no real purpose other than capitalizing on the hype surrounding blockchain technology are now under Securities and Exchange Commission (SEC) scrutiny. Detailed in a recent Reuters article (http://ibn.fm/kldP6), SEC Chairman Jay Clayton cautioned that it was not acceptable for companies without a meaningful track record in the sector to dabble in blockchain technology, change their name, then offer investors securities without providing adequate disclosures around the risks involved.

This latest SEC salvo targets the nefarious underbelly of crypto-mania. The SEC has temporarily suspended trading in unwarranted high flyers and “is looking closely at the disclosures of public companies that shift their business models to capitalize on the perceived promise of distributed ledger technology and whether the disclosures comply with the securities laws, particularly in the case of an offering,” as noted by Clayton. Clayton also said the SEC had seen unsettling evidence that legal professionals have incorrectly advised clients they don’t have to comply with federal securities laws in initial coin offerings (ICOs) where cryptocurrency start-ups solicit funds from investors.

The SEC’s warnings are in line with other countries’ efforts around the globe to limit speculation in cryptocurrencies. The SEC has warned investors about cryptocurrency frauds and openly stated that ICO fundraisings should comply with securities laws.

If double-digit price swings and threats of government intervention aren’t enough to keep crypto investors on edge, a new research report from Ernst & Young (http://ibn.fm/301I2) reveals that more than 10 percent of funds raised through “initial coin offerings” are either lost or stolen in hacker attacks.

The SEC is right to reign in fraudulent crypto-mania. Until controls are established and markets regulated, caveat emptor (buyer beware).

SinglePoint, Inc. (SING) Remains Bullish Regarding Use of Bitcoin, Blockchain Technologies to Solve Cannabis Industry’s Payment Problems

  • Company’s bitcoin payments solution allows underbanked cannabis merchants to accept bitcoin-backed card transactions
  • Proprietary bitcoin exchange soft-launched in November 2017; official launch scheduled for Q1 2018
  • Company recently announced LOI to acquire Bitcoin Beyond

SinglePoint, Inc. (OTC: SING) has evolved from a full-service mobile technology provider to a publicly traded holding company, diversifying into horizontal markets and building a robust portfolio and a diversified holding base by acquiring an interest in undervalued subsidiaries. Through subsidiary company SingleSeed, SinglePoint is successfully offering products and services to the cannabis industry, including, notably, a proprietary bitcoin payments solution that enables both cannabis merchants and consumers to make bitcoin-powered transactions using debit and credit cards. This was discussed in detail in a recent article (http://ibn.fm/Rc6xP).

This innovative solution is fully KYC-AML compliant and also has applicability that transcends the cannabis industry and can be deployed in various kinds of businesses to allow the completion of bitcoin transactions using payment cards. Such a solution is ideal for underbanked markets like the cannabis industry, which currently lacks traditional banking options in the United States due to its continued federal status as a Schedule I drug. Where U.S. cannabis vendors have primarily been forced to deal in cash, bitcoin solutions like that offered by SinglePoint allow customers to make convenient card-based purchases, just as they would in other types of stores while buying any other type of merchandise.

In any state where cannabis enjoys legal status, the SingleSeed payments platform can be used. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system further deducts items automatically from a dispensary’s product listings when a purchase is made.

SinglePoint’s proprietary solution, SingleSeed Payments (http://ibn.fm/73r3k), was soft-launched in November 2017, and the official launch of the payments solution is scheduled to take place during Q1 of 2018.

The benefits of SinglePoint’s bitcoin solution in providing payment options while cannabis remains federally illegal are clear. However, should cannabis be legalized at the federal level in the U.S. at some future point, the SingleSeed app will not cease to be needful but is actually positioned to expand as a useful tool for managing cryptocurrency-based retail cannabis payments. The company also has traditional payment solutions ready to go in the event that banks start accepting cannabis businesses for merchant processing.

The ultimate aim of SinglePoint is to offer a fully integrated solution that can be utilized for end-to-end management by businesses of all types.

SinglePoint’s management team continues to be bullish regarding the use of bitcoin and blockchain technologies as means of overcoming key obstacles within the cannabis market. The company plans to seek out acquisitions and partnerships with other entities during 2018 to continue bringing innovative solutions to this burgeoning market. One such effort was announced on January 23, when SinglePoint announced a letter of intent to acquire 100 percent of premier web-enabled, point-of-sale bitcoin payments platform Bitcoin Beyond (http://ibn.fm/TtIqO).

For more information, visit the company’s website at www.SinglePoint.com

Let us hear your thoughts: SinglePoint, Inc. Message Board

IEG Holdings Corp. (IEGH) Exploring Creation of Gold Metal-backed Cryptocurrency

  • Negotiations underway to purchase a verified gold project with prospecting licenses
  • IEGH’s cryptocurrency to be backed by gold metal, registered with SEC as a security
  • Volatility of cryptocurrency could potentially be stabilized with precious metal backing

Consumer loan provider IEG Holdings Corp. (OTCQB: IEGH), through wholly owned subsidiary Investment Evolution Crypto, LLC. (“Crypto”), recently announced its intention to create its own gold metal-backed cryptocurrency that could potentially be utilized when offering loans and accepting loan repayments. While Crypto is in the development planning stages and exploring the opportunities presented by crypto/blockchain technologies, the company is already negotiating to purchase a bona fide gold project with established gold metal in the ground and prospecting licenses on record.

In a news release announcing the company’s venture (http://ibn.fm/flkVE), Paul Mathieson, IEG Holdings chairman and CEO, said, “We believe potentially combining the exciting new blockchain technology with the hard asset of gold metal, expected SEC registration, a leading sophisticated online consumer finance system and individual US state lending licenses is a very exciting proposition… In addition, we believe the future leaders of the crypto/blockchain sector will be companies that are materially compliant with all the existing and future related US government legislation. We aim for IEGH to leverage off its existing fintech business credentials, specifically its extensive experience in online consumer loans, to potentially be a key player in the crypto/blockchain sector.”

This attention to detail and meeting regulatory necessities is the backbone of IEGH’s success as a publicly traded, global leader in consumer finance (http://ibn.fm/0pXBq). The company provides small online personal loans of $5,000 to $10,000 in the United States via a state-licensed operating subsidiary, Investment Evolution Corporation, under the consumer brand ‘Mr. Amazing Loans’.

The company originates, processes, and services consumer loans from its centralized Las Vegas headquarters. Loans are offered in 20 states via its online platform and distribution network. IEGH is a licensed direct lender with state licenses and/or certificates of authority to lend in each state and offers all loans within the prevailing statutory rates. The difference for consumers seeking a personal loan under Mr. Amazing Loans’ terms is the ability to repay the loan with low, fixed repayment schedules that fit into their lifestyle and budget. Since inception, the company has provided over $16 million in consumer loans – a cumulative loan volume increase of 192 percent from January 2015 to the end of 2017 (http://ibn.fm/UroRz).

The coming year includes some exciting business opportunities for IEG Holdings, its subsidiaries and investors. Exploration of the legalities, economic risks and benefits of accepting repayment of customer loans in the form of leading crypto/blockchain currencies such as bitcoin, and also possibly creating and issuing a precious metal-backed cryptocurrency, are seen as prime targets for 2018.

For more information, visit the company’s website at www.InvestmentEvolution.com

Let us hear your thoughts: IEG Holdings Corporation Message Board

Liberty Leaf Holdings Ltd. (OTCQB: LIBFF) (CSE: LIB) (FSE: HN3P) Closes $2 Million in Private Placement Financing

  • Company’s subsidiaries set sights on recreational use licensing, expansion
  • Total marijuana market in Canada forecast to hit $2.8 billion by 2020
  • Pet cannabis products for pain expected to form large market opportunity

Liberty Leaf Holdings Ltd. (OTCQB: LIBFF) (CSE: LIB) (FSE: HN3P) announced on January 22 that it had closed a private placement financing effort with $2 million in gross proceeds that will be used to speed completion of facility construction projects for its subsidiaries, North Road Ventures in the greater Vancouver area of Canada’s British Columbia and Just Kush Enterprises, located some 250 miles to the east. Just Kush has a license to cultivate medicinal-use marijuana at its Oliver facility and is applying for a license to produce recreational marijuana in anticipation of national legalization in July. North Road is a distributor of cannabis products to licensed retailers with plans to expand into the recreational market upon legalization.

“Liberty Leaf is pleased to have cornerstone investors from the cannabis industry participate in our equity offering,” Will Rascan, president and CEO of Liberty Leaf, stated in a news release about the closing (http://ibn.fm/XxHW7).

Liberty Leaf created and issued five million units priced at $0.40 each that comprise a common share and half of a transferable share purchase warrant, and buyers were granted the option of purchasing an additional common share of the company at a PPS of $0.60 for each whole warrant they hold during the next 24 months.

The company continues to seek out revenue-generating cannabis-related ventures and general working capital. Liberty Leaf’s focus is on establishing a diverse portfolio within the rapidly growing legal cannabis industry’s supply chain, including value-added marijuana-based pet pain products that could become the company’s largest market opportunity of all. North Road Ventures has stated in its recreational license application to Health Canada that it plans to double its cannabis product lines and increase its vault storage capacity by 500 percent. The increase is part of an effort to ensure supply line adequacy as recreational use legalization approaches, and the company cites difficulties in Nevada as an example of what it wants to avoid — Nevada’s governor issued a statement of emergency when it became clear recreational marijuana supplies were running low shortly after that state’s legalization decision, which put tax dollars on the line and drove the state tax commission to evaluate whether there were enough distributors to supply all of the dispensaries.

Recreational use has clearly been the great revenue driver thus far in locations where marijuana has been legalized. In Colorado, for example, where legalized recreational use is in its fourth year, the sales split is about 70 percent recreational to 30 percent medicinal, according to tax data cited by the company (http://ibn.fm/4F4eE), with aggregate cannabis sales totaling $227 million during the first two months of 2017 — a 30 percent increase from the prior year.

Statista projects that, if Canada legalizes recreational use marijuana in July as expected, the combined market for dried and oil/extract marijuana will reach C$2.8 billion within three years (http://ibn.fm/nhg4d).

Liberty Leaf also has professional partnerships with Esev Genetics, billed as “the world’s first genomic platform for high value crop,” and Blox Labs, a software solutions company focused on blockchain and other decentralized application technologies, to help ensure additional aspects of the supply chain.

For more information, visit the company’s website at www.LibLeaf.ca

Proposed Transdermal Treatment for Veterans with PTSD a Top Priority of Skinvisible, Inc. (SKVI) and Quoin Pharmaceuticals

  • Proposed transdermal product will help veterans struggling with PTSD and suicidal thoughts
  • Majority of suicides among military veterans are among those 50 and older
  • Suicide rate for U.S. women veterans was 2.5 times higher than civilian adult women
  • Presidential executive order signed January 9, 2018, focuses on providing mental health care to former service members

Topical and transdermal product development company Skinvisible, Inc. (OTCQB: SKVI) and its patented Invisicare® technology could provide significant relief to veterans with post-traumatic stress disorder through a proposed transdermal treatment the company expects to develop as it merges with Quoin Pharmaceuticals Ltd. The proposed merger, announced in November 2017 (http://ibn.fm/NBrxz), will create a robust product portfolio addressing major unmet medical needs, including the devastating number of veteran suicides that occur daily. The company anticipates that the merger will take place in early 2018.

Skinvisible, through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., has already developed, licensed and sold multiple dermatology and health care products, as well as various medical treatments, using its patented Invisicare® technology (http://ibn.fm/fAWss). The proposed merger with Quoin Pharmaceuticals would combine Skinvisible’s patented and proven novel drug delivery technologies that enhance the delivery of various active ingredients with Quion’s strong pharmaceutical background in post-surgical pain and promising approach to PTSD treatment.

Quoin’s two lead products are targeting crises that result in the death of almost 120 people in the U.S. every day. Data released September 15, 2017, by the U.S. Department of Veteran Affairs (“VA”) show that the risk for suicide was 22 percent higher among veterans when compared to civilians. Among the 20 suicides per day reported to the VA in 2016, 14 of those veterans were not under VA care, VA Secretary Dr. David J. Shulkin stated in presenting the report (http://ibn.fm/KlsbS).

“These findings are deeply concerning, which is why I made suicide prevention my top clinical priority,” Shulkin continued. “This is a national public health issue that requires a concerted, national approach.”

Quoin’s proposed product, QRX002, will be a once-daily transdermal NMDA receptor antagonist for the treatment of suicidal ideation in military veterans with PTSD. About eight million adults are living with PTSD, with anywhere from 11 percent to 20 percent of military veterans experiencing the disorder (http://ibn.fm/eqdaf). Currently, the only approved medical treatments for PTSD are standard anti-depressants, which are either ineffective or act very slowly, resulting in a clear unmet medical need to address this growing crisis. Quoin believes that QRX002 may be a candidate for both orphan drug status and breakthrough therapy designation.

“Skinvisible has done an impressive job developing their technology and building a very robust patent portfolio,” Dr. Michael Myers, chairman and CEO of Quoin Pharmaceuticals, stated in a news release. “The utilization of their unique drug delivery technology could, we believe, enable us to achieve the performance targets of our proposed lead products whilst providing for strong patent protection.”

Highlighting the terrible cost that PTSD delivers to the nation’s veterans and their families, President Donald Trump signed an executive order on January 9, 2018, aimed at reducing veteran suicides (http://ibn.fm/X0uah). The mandate, ‘Supporting Our Veterans During Their Transition from Uniformed Service to Civilian Life’, offers more former service members access to mental health care and focuses on those who are soon-to-leave military service, since they have the highest risk for suicide.

For more information, visit the company’s website at www.Skinvisible.com

Let us hear your thoughts: Skinvisible, Inc. Message Board

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) Looks to Set Another Industry Milestone

  • Petroteq was a pioneer in the environmentally safe extraction of heavy oils with patented technologies
  • Company’s blockchain initiative, PetroBLOQ, will be first blockchain platform developed exclusively for the supply chain needs of the oil and gas sector
  • Examining company history of value creation, PetroBLOQ may be largest value driver yet

Cryptocurrencies have garnered enormous market attention lately. Some say cryptocurrencies are worthless, others say they’re the new global fiat medium of exchange. Time will tell. However, there is consensus that the underlying blockchain technology has applications that extend far beyond its connections to cryptocurrency. Companies around the globe are beginning to employ blockchain technology to streamline business and secure transactions.

Blockchain is an encrypted electronic ledger, replicated across a network of multiple computer nodes. This distributed ledger virtually eliminates the need for supervision and administration of records. Since this open and distributed record-keeping system is decentralized, blockchain is self-monitored by all of the linked computers. Blockchain can reduce costs whiles providing data security and reliability and eliminating the need for third party reconciliation (e.g. banks, clearing houses). “Blockchain, the digital record-keeping method that exploded in popularity in conjunction with the cryptocurrency craze, will change the way the world makes transactions,” IBM’s Martin Schroeter recently told CNBC (http://ibn.fm/BYOsA).

With such dynamic, complex and fungible markets, the oil and gas industry is likely to be one of the largest beneficiaries of blockchain. The recent article ‘Expectations for 2018 on Blockchain Applications in the Energy Industry’ (http://ibn.fm/FEKst) details both the industry challenges and the blockchain solutions being developed by Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF). Petroteq Energy, a multifaceted energy company, was a pioneer in the environmentally safe extraction of heavy oils from oil sands and oil shale deposits with its patented technologies that produce zero greenhouse gas and zero waste.

Petroteq’s new blockchain initiative, PetroBLOQ (www.PetroBLOQ.com), looks to set another industry milestone and will be the first blockchain-based platform developed exclusively for the supply chain needs of the oil and gas sector.

The oil and gas industry supplies vital commodities that are subject to constant price fluctuations, supply and demand imbalances and geopolitical pressures. Petroteq’s PetroBLOQ blockchain solution targets these complex variables as well as the risk and expense in the exploration and production of oil and gas. With over 35 billion barrels of oil produced each year, saving even a small percentage by managing supply and distribution can have a huge bottom line impact. Petroteq’s PetroBLOQ blockchain industry first solution aims to deliver cost and time savings, greater efficiency, flexibility and transparency and the ability to more effectively manage market fluctuations.

Petroteq has a history of creating value by identifying industry problems and delivering solutions, as it did with its patented, environmentally friendly heavy oil extraction technologies. Petroteq has intentions of creating enormous new value with its recent blockchain initiative, PetroBLOQ.

For more information, visit the company’s website at www.Petroteq.energy

Let us hear your thoughts: Petroteq Energy Inc. Message Board

From Our Blog

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

March 28, 2024

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for the period ended December 31, 2023, and provided a corporate update (https://ibn.fm/iORBu). Results from multiple studies using Longeveron’s lead investigational therapeutic candidate, Lomecel-B(TM), were announced by the company last year. “In 2023 […]

Rotate your device 90° to view site.